Cullinan Oncology, Inc. (CGEM) Bundle
A Brief History of Cullinan Therapeutics, Inc.
Company Overview
Cullinan Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapies for patients with cancer. The company was founded with the goal of advancing the treatment landscape through its proprietary drug candidates and strategic partnerships.
Financial Performance
As of September 30, 2024, Cullinan Therapeutics reported the following financial highlights:
| Financial Metric | 2024 (9 Months Ended Sept 30) | 2023 (9 Months Ended Sept 30) |
|---|---|---|
| Net Cash Used in Operating Activities | $108.7 million | $116.1 million |
| Net Cash Used in Investing Activities | $152.3 million | $15.7 million |
| Net Cash Provided by Financing Activities | $264.6 million | $40.5 million |
| Net Increase (Decrease) in Cash and Cash Equivalents | $3.7 million | ($91.3 million) |
Private Placement and Capital Raising
In April 2024, Cullinan completed a private placement, issuing approximately 14.4 million shares of common stock and pre-funded warrants for an additional 0.3 million shares, raising net proceeds of $262.7 million after deducting offering costs of $17.3 million.
Cash Position
As of September 30, 2024, the company had total cash, cash equivalents, and short-term investments of $578.1 million, along with long-term investments and interest receivable amounting to $60.9 million.
Research and Development Expenses
For the nine months ended September 30, 2024, Cullinan reported total research and development expenses of $102.4 million, compared to $113.3 million in the same period of 2023. The breakdown of these expenses is detailed in the table below:
| Research and Development Expenses (in $ thousands) | 2024 (9 Months Ended Sept 30) | 2023 (9 Months Ended Sept 30) |
|---|---|---|
| CLN-978 | $10,849 | $3,874 |
| CLN-619 | $21,802 | $17,804 |
| Zipalertinib | $23,110 | $20,005 |
| CLN-049 | $7,857 | $6,838 |
| Total R&D Expenses | $102,411 | $113,308 |
Company Losses
Cullinan continues to experience significant operating losses. For the nine months ended September 30, 2024, the net loss attributable to common stockholders was $119.7 million, compared to $129.4 million in the same period of 2023. The comprehensive loss for the same periods is outlined below:
| Comprehensive Loss (in $ thousands) | 2024 (9 Months Ended Sept 30) | 2023 (9 Months Ended Sept 30) |
|---|---|---|
| Net Loss | $119,928 | $129,538 |
| Unrealized Gain on Investments | $1,099 | $1,550 |
| Comprehensive Loss | $118,829 | $127,988 |
Accumulated Deficit
As of September 30, 2024, Cullinan Therapeutics had an accumulated deficit of $320.6 million, indicating a continued reliance on external funding to support its operational and developmental activities.
Equity-Based Compensation
For the nine months ended September 30, 2024, Cullinan reported equity-based compensation expenses totaling $28.2 million, compared to $22.9 million in the same period of 2023.
Future Outlook
Looking ahead, Cullinan Therapeutics anticipates continued investment in research and development, with plans to fund operations through existing cash reserves and potential future capital raises.
A Who Owns Cullinan Oncology, Inc. (CGEM)
Ownership Structure
As of 2024, Cullinan Oncology, Inc. (CGEM) has a diversified ownership structure comprising institutional investors, individual shareholders, and insiders. The breakdown of ownership is as follows:
| Ownership Type | Percentage Ownership |
|---|---|
| Institutional Investors | Approximately 70% |
| Insiders (Executives and Board Members) | Approximately 10% |
| Retail Investors | Approximately 20% |
Major Shareholders
The following table outlines the major shareholders of Cullinan Oncology, Inc., including their ownership stakes as of the latest data in 2024:
| Shareholder Name | Type | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Biotechnology Value Fund, L.P. | Institutional | 6,500,000 | 11.16% |
| MSI BVF SPV, LLC | Institutional | 4,500,000 | 7.73% |
| BlackRock, Inc. | Institutional | 3,200,000 | 5.52% |
| Biotechnology Value Fund II, L.P. | Institutional | 3,000,000 | 5.19% |
| Insider Holdings (combined) | Insiders | 5,800,000 | 10.00% |
Recent Financing Activities
In April 2024, Cullinan completed a private placement, issuing approximately 14.4 million shares of common stock and pre-funded warrants, netting proceeds of $262.7 million after deducting offering costs. This significant capital raise indicates strong institutional interest and support for the company's strategic direction.
Cash Position and Financial Health
As of September 30, 2024, Cullinan reported cash, cash equivalents, and short-term investments totaling $578.1 million, with long-term investments and interest receivable amounting to $60.9 million. The company has had a history of operating losses, with a reported net loss of $119.9 million for the nine months ended September 30, 2024.
Net Loss and Earnings Per Share
For the three months ended September 30, 2024, Cullinan reported a net loss attributable to common stockholders of $40.6 million, translating to a basic and diluted loss per share of $0.69. The company's accumulated deficit as of September 30, 2024, stood at $320.6 million.
Future Outlook
Cullinan has indicated that its current cash position is expected to fund operations for at least the next twelve months. The company's ability to secure additional financing will be crucial for sustaining its research and development initiatives, as it has not yet commercialized any products.
Equity-Based Compensation
In the nine months ended September 30, 2024, Cullinan recorded equity-based compensation expenses totaling $28.2 million. This reflects the company's strategy to attract and retain talent through incentive compensation aligned with shareholder interests.
Cullinan Oncology, Inc. (CGEM) Mission Statement
Cullinan Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to creating new standards of care for patients suffering from cancer. The company's mission is to identify high-impact targets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells. Cullinan aims to select optimal therapeutic modalities for these targets, sourcing innovation both internally and externally, focusing on product candidates with novel technology or differentiated mechanisms.
Financial Overview
As of September 30, 2024, Cullinan Oncology reported:
- Cash, cash equivalents, and short-term investments: $578.1 million
- Long-term investments and interest receivable: $60.9 million
- Accumulated deficit: $320.6 million
- Net loss for the three months ended September 30, 2024: $40.56 million
- Net loss for the nine months ended September 30, 2024: $119.93 million
- Research and development expenses for the three months ended September 30, 2024: $35.51 million
- General and administrative expenses for the three months ended September 30, 2024: $13.35 million
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Loss | $40.56 million | $39.18 million | $119.93 million | $129.54 million |
| Research and Development Expenses | $35.51 million | $33.82 million | $102.41 million | $113.31 million |
| General and Administrative Expenses | $13.35 million | $10.98 million | $39.46 million | $31.86 million |
| Total Operating Expenses | $48.85 million | $44.80 million | $141.87 million | $145.16 million |
| Cash Used in Operating Activities | $108.68 million | $116.14 million | N/A | N/A |
| Cash Provided by Financing Activities | $264.61 million | $40.50 million | N/A | N/A |
Research and Development Focus
Cullinan is actively engaged in the research and development of multiple clinical-stage product candidates. The following are significant expenditures for the three months ended September 30, 2024:
| Product Candidate | Q3 2024 Expenses (in thousands) | Q3 2023 Expenses (in thousands) |
|---|---|---|
| CLN-978 | $4,888 | $2,231 |
| CLN-619 | $7,120 | $7,301 |
| Zipalertinib | $7,596 | $6,593 |
| CLN-049 | $2,943 | $2,045 |
| CLN-617 | $2,142 | $2,146 |
| CLN-418 | $927 | $5,535 |
| Total R&D Expenses | $35,506 | $33,821 |
Cullinan has not yet generated any revenue from the sale of products and does not anticipate generating revenue in the near future.
How Cullinan Oncology, Inc. (CGEM) Works
Company Overview
Cullinan Oncology, Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. As of September 30, 2024, the company had total assets amounting to $653.3 million, with a significant portion held in cash and equivalents of $578.1 million.
Financial Performance
For the three months ended September 30, 2024, Cullinan reported a net loss of $40.6 million, compared to a net loss of $39.2 million for the same period in 2023. For the nine months ended September 30, 2024, the net loss was $119.9 million, down from $129.5 million in 2023.
Cash Flow Analysis
The following table summarizes the cash flow activities for Cullinan Oncology for the nine months ended September 30, 2024 and 2023 (in thousands):
| Cash Flow Activity | 2024 | 2023 |
|---|---|---|
| Net cash used in operating activities | $(108,677) | $(116,144) |
| Net cash used in investing activities | $(152,278) | $(15,664) |
| Net cash provided by financing activities | $264,606 | $40,503 |
| Net increase (decrease) in cash and cash equivalents | $3,651 | $(91,305) |
Research and Development Expenses
Research and development expenses for the three months ended September 30, 2024, totaled $35.5 million, compared to $33.8 million for the same period in 2023. For the nine months ended September 30, 2024, these expenses totaled $102.4 million, down from $113.3 million in 2023.
Product Development Pipeline
Cullinan's pipeline includes several clinical-stage product candidates. The following table summarizes research and development expenses by individual product candidates for the three and nine months ended September 30, 2024 (in thousands):
| Product Candidate | 3 Months Ended 9/30/24 | 3 Months Ended 9/30/23 | 9 Months Ended 9/30/24 | 9 Months Ended 9/30/23 |
|---|---|---|---|---|
| CLN-978 | $4,888 | $2,231 | $10,849 | $3,874 |
| CLN-619 | $7,120 | $7,301 | $21,802 | $17,804 |
| Zipalertinib | $7,596 | $6,593 | $23,110 | $20,005 |
| CLN-049 | $2,943 | $2,045 | $7,857 | $6,838 |
| CLN-617 | $2,142 | $2,146 | $5,186 | $6,191 |
| CLN-418 | $927 | $5,535 | $6,036 | $33,505 |
Equity and Financing Activities
In April 2024, Cullinan completed a private placement, issuing approximately 14.4 million shares of common stock and receiving net proceeds of $262.7 million after deducting offering costs.
Operating Leases
Cullinan has an operating lease for approximately 14,000 square feet of office space in Cambridge, Massachusetts. The lease commenced in August 2022 and is set to expire in July 2026. The total future minimum lease payments as of September 30, 2024, amount to $2.7 million.
Stockholders' Equity
As of September 30, 2024, Cullinan had total stockholders' equity of $627.9 million, compared to $453.7 million at the end of 2023.
How Cullinan Oncology, Inc. (CGEM) Makes Money
Revenue Generation
Cullinan Oncology, Inc. has not generated any revenue from product sales since its inception and does not expect to do so in the near future. The company has primarily funded its operations through equity securities and licensing agreements.
Funding and Capital Structure
As of September 30, 2024, Cullinan had:
- Cash, cash equivalents, and short-term investments: $578.1 million
- Long-term investments and interest receivable: $60.9 million
- Accumulated deficit: $320.6 million
In April 2024, the company raised $262.7 million through a private placement of common stock and pre-funded warrants.
Operating Expenses
For the nine months ended September 30, 2024, Cullinan's operating expenses were as follows:
| Category | Amount (in thousands) |
|---|---|
| Research and Development | $102,411 |
| General and Administrative | $39,460 |
| Total Operating Expenses | $141,871 |
The company reported a net loss of $119.9 million for the nine months ended September 30, 2024.
Research and Development Expenses
The breakdown of research and development expenses for the three and nine months ended September 30, 2024 is as follows:
| Product Candidate | Three Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2024 (in thousands) |
|---|---|---|
| CLN-978 | $4,888 | $10,849 |
| CLN-619 | $7,120 | $21,802 |
| Zipalertinib | $7,596 | $23,110 |
| CLN-049 | $2,943 | $7,857 |
| CLN-617 | $2,142 | $5,186 |
| CLN-418 | $927 | $6,036 |
| Total | $35,506 | $102,411 |
Research and development remains a significant focus, with total expenses reflecting the company's commitment to advancing its therapeutic candidates.
Investment Activities
During the nine months ended September 30, 2024, Cullinan's cash flow from investing activities included:
- Net cash used: $152.3 million
- Purchases of marketable securities: $553.1 million
- Proceeds from the maturities of marketable securities: $400.8 million
This reflects a strategic approach to managing cash reserves while investing in potential growth opportunities.
Financing Activities
For the nine months ended September 30, 2024, net cash provided by financing activities was $264.6 million, primarily from:
- Net proceeds from the issuance of common stock: $262.7 million
- Net proceeds from equity-based compensation plans: $6.4 million
- Acquisition of noncontrolling interests: ($4.4 million)
This financing strategy underscores the company's reliance on equity markets to fund its operations.
Intellectual Property and Partnerships
Cullinan holds significant intellectual property rights, including:
- CLN-619: 99% ownership
- CLN-049: 97% ownership
- CLN-617: 94% ownership
Additionally, Cullinan is co-developing zipalertinib with Taiho, which holds the intellectual property rights.
Cullinan Oncology, Inc. (CGEM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Cullinan Oncology, Inc. (CGEM) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Cullinan Oncology, Inc. (CGEM)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Cullinan Oncology, Inc. (CGEM)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.